Local Coverage Determination (LCD)

Surgical Treatment of Nails

L33833

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
First Coast Service Options, Inc.	A and B MAC	09101 - MAC A	J - N	Florida
First Coast Service Options, Inc.	A and B MAC	09102 - MAC B	J - N	Florida
First Coast Service Options, Inc.	A and B MAC	09201 - MAC A	J - N	Puerto Rico Virgin Islands
First Coast Service Options, Inc.	A and B MAC	09202 - MAC B	J - N	Puerto Rico
First Coast Service Options, Inc.	A and B MAC	09302 - MAC B	J - N	Virgin Islands

LCD Information

Document Information

LCD ID
L33833

LCD Title
Surgical Treatment of Nails

Proposed LCD in Comment Period
N/A

Source Proposed LCD
DL33833

Original Effective Date
For services performed on or after 10/01/2015

Revision Effective Date
For services performed on or after 01/30/2022

Revision Ending Date
N/A

Retirement Date
N/A

Notice Period Start Date
12/16/2021

Notice Period End Date
01/29/2022

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Issue

Issue Description

Based on current literature evidence findings, the history/background section, indications, and limitations sections were updated to remove the language that is not supported by literature and add the verbiage that is. A summary of evidence, analysis of evidence, section was updated to add the findings and verbiage noted in the LCD. The Bibliography was updated to add the current references. Also, formatting changes were made throughout the LCD.

CMS National Coverage Policy

This LCD supplements but does not replace, modify or supersede existing Medicare applicable National Coverage Determinations (NCDs) or payment policy rules and regulations for surgical treatment of nails. Federal statute and subsequent Medicare regulations regarding provision and payment for medical services are lengthy. They are not repeated in this LCD. Neither Medicare payment policy rules nor this LCD replace, modify or supersede applicable state statutes regarding medical practice or other health practice professions acts, definitions and/or scopes of practice. All providers who report services for Medicare payment must fully understand and follow all existing laws, regulations and rules for Medicare payment for surgical treatment of nails and must properly submit only valid claims for them. Please review and understand them and apply the medical necessity provisions in the policy within the context of the manual rules. Relevant CMS manual instructions and policies may be found in the following Internet-Only Manuals (IOMs) published on the CMS Web site:

IOM Citations:

CMS IOM 100-08, Medicare Program Integrity Manual,
- Chapter 13, Section 13.5.4 Reasonable and Necessary Provision in an LCD

Social Security Act (Title XVIII) Standard References:

Title XVIII of the Social Security Act, Section 1862(a)(1)(A) states that no Medicare payment may be made for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury.
Title XVIII of the Social Security Act, Section 1862(a)(7). This section excludes routine physical examinations.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

Compliance with the provisions in this LCD may be monitored and addressed through post payment data analysis and subsequent medical review audits.

History/Background and/or General Information

There are a number of indications for surgical exploration of the nail unit of the fingers and toes. Surgical nail avulsion may be performed to aid in diagnosis by allowing for the full examination and exploration of the nail bed, the nail matrix, the proximal nail fold (the soft tissue that protects the emerging nail plate), the lateral nail fold (LNF) (extension of the proximal nail fold that protects each side of the nail plate), and the nail grooves for the presence of pathology or as a preliminary step before performing a biopsy on the nail bed and the nail matrix. Indications such as subungual hematomas and tumors, benign or malignant neoplasms and trauma may require access and visualization of the nail bed. Surgical nail avulsion may also be performed for therapeutic management of disease processes, to relieve pain or to correct or prevent anatomical deformities of the nail. Symptomatic disease processes affecting the nail complex that may be managed with surgical intervention include infections, inflammation, onychomycosis (i.e., fungal infection), onychocryptosis (i.e., ingrown nails), onychogryphosis (i.e., hornlike hypertrophy of the nail plate), and onychauxis (i.e., thickened nails), as well as psoriasis, lichen planus, congenital nail dystrophies,¹ and tumors.²Nail treatment and surgical options must be individualized based on the nail condition and careful consideration should be taken when selecting patients for surgical nail procedures. Factors to consider when determining appropriate treatment include the extent of disease, type of organism, and medical comorbidities.¹Patients with factors that predispose them to infection include but are not limited to those with uncontrolled diabetes mellitus, prior infection with methicillin-resistant Staphylococcus aureus, and immunosuppression.

Medical conditions that impede blood flow or depress immunity may increase the risk of fungal nail infection. Diabetes and circulatory disorders may impair blood flow to the nail beds, increasing the chance of fungal infection. Prevalence in the general population ranges from 2.5% - 5% and is more common in diabetics (13% - 32%). Diabetics, and others suffering from impaired arterial circulation and decreased sensation, may present with more severe cases (i.e., secondary infection, gangrene).^3,4,5Ingrown toenails account for approximately 20% of foot problems presented in the primary care setting.⁶An ingrown nail is a condition which results in the growth of the nail edge into the surrounding soft tissue that may result in pain, inflammation, or infection. This condition, although not very often, may involve the fingernails, and is noted in the literature to commonly occur in the great toes.^1,6 No consensus has been reached for the best treatment approach, but ingrown nails may be treated non-surgically or surgically. Non-surgical treatments are typically used for mild to moderate ingrown nails, whereas surgical treatments are typically used in moderate and severe cases.^1,3,6Blood underneath a fingernail or toenail or a subungual hematoma, generates pressure between the nail bed and the nail plate where the blood collects and may cause pain. Treatment of a subungual hematoma depends on the type of injury and patient comorbidities or risk factors for complications. A small not too painful hematoma is incorporated into the nail and progressively migrates outward to the free edge of the nail plate as the nail grows out.

In traumatic nail injuries, surgical nail avulsion may be used to evaluate the stability of the nail bed or to release a subungual hematoma after a failed puncture aspiration. Injury of a fingernail may be treated with avulsion with surgical repair of the nail bed.^1,10 For toenail avulsions, a nonadherent, highly absorbent dressing is ideal.¹⁰ A reattachment of the avulsed fingernail or a fingernail substitute, intended to protect the nail bed during the healing process, will adhere to the nail bed within 1 to 3 months and will be pushed off by the new nail, and as noted in this situation, will reach complete growth in 4 to 6 months.⁸The thickening of the nail plate may be a symptom of nail fungus, psoriasis or other conditions. This thickening (Onychauxis) may force the nail plate to separate from the nail bed (Onycholysis). This condition may last for several months because the finger or toenail will not reattach to its nail bed. Non-surgical treatment consists of clipping off the affected separated portion at the distal end of the of the nail plate and treating the underlying cause. In the case of moderate or severe symptomatic dystrophic nail plate, a surgical intervention may be required.^1,3,6A partial or complete avulsion of a nail plate is generally performed under local anesthesia. This surgical procedure involves the separation and a partial removal of a border of the nail plate or removal of the entire nail plate from the nail bed to the eponychium; the surgical removal of the body of the nail plate from its primary attachments, the nail bed ventrally and the proximal nail fold dorsally.

Excision of nail plate and nail matrix is performed under local anesthesia and requires removal of the full length or the entire nail plate, with destruction or permanent removal of the matrix (matrixectomy). Matrixectomy can be performed surgically, chemically, electrosurgically, or with radiofrequency ablation. All are effective options when treating ingrown toenails.⁶ Partial matrixectomies may be performed in the management of persistent onycholysis and onychocryptosis. When performed without matrixectomy, in most cases, the nail will regrow from the area under the cuticle (the matrix). A fingernail takes about 4 to 6 months to grow back. A toenail takes about 8 to 12 months to grow back.^7,8Wedge excision of skin of the nail fold is designed to relieve pressure on the nail/soft tissue and is an excision of the skin from the involved, medial and/or lateral, side of the toe or finger. The technique of wedge excision often fails to remove the nail spicule. Nail removal without destroying the matrix of the nail that produces nail growth can permit the nail to regrow beneath the nail fold, producing another ingrown nail. The purpose of partial or complete removal of a nail is to decrease the width of the nail plate at the offending border to relieve pain and pressure. This procedure could include removal/destruction of the nail matrix, either surgically or chemically, to cause long-term narrowing of the nail plate.^3,6Covered Indications

Avulsion of the nail plate, excision of the nail and nail matrix, and wedge excision of the skin of the nail fold are considered medically reasonable and necessary for the following indications:

Symptomatic onychocryptosis (ingrown fingernails or toenails)^1,4,7,8
Subungual abscess and/or hematoma^7,9,10
Subungual and periungual tumors^2,9
Injury of the toes or fingers involving the nail component to evaluate the stability of the nail bed or to release a subungual hematoma after a failed puncture aspiration^1,7,11
Severe or recurrent fungal nail infection that has failed to respond to usual, less invasive treatment (for example, pharmacological treatment, debridement)
For diagnosis of suspected lichen planus or psoriasis of the fingernail or toenail^{2, 9,10}
Onychogryphosis or onychauxis¹
Congenital or acquired nail dystrophies that jeopardize the integrity of the finger or toe^1,2,10

Limitations

The following are considered not medically reasonable and necessary:

Nail debridement or removing small chips or wedges of the nail and/or skin that does not require local anesthesia does not constitute surgical treatment of a nail^3,6,11
Trimming, cutting, or clipping of the distal unattached nail margins does not constitute surgical treatment of a nail^3,6,11
Surgical treatment of asymptomatic conditions^3,6
Repeat nail avulsion on the same toe or finger following a complete nail avulsion performed more frequently than every 8 months (32 weeks) for toenails or 4 months (16 weeks) for fingernails^7,10
Repeat nail excision on the same toe or finger following a complete nail excision for permanent removal

Provider Qualifications

Services will be considered medically reasonable and necessary when all aspects of care are within the scope of practice of the provider’s professional licensure, when performed according to the supervision requirements per state scope of practice laws, and when all procedures are performed by appropriately trained providers in the appropriate setting.

Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this LCD, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

Summary of Evidence

The content of this LCD is supported through an evidence-based literature search of articles and publications through PubMed. Articles were identified based on a key word search for: indications for the surgical treatment of nails, ingrown toenails. The literature search was filtered to find articles within 5 to 10 years. Also included were full text articles, clinical trials, randomized controlled trials, and systematic reviews. Below is a summary of evidence to support the medically reasonable and necessary indications for the surgical treatment of nails and explanation of limitations.

Yaemsiri et al conducted a study of human nail clippings for epidemiological studies as a biomarker for assessing diet and environmental exposure to trace elements or other chemical compounds. To the authors knowledge at the time of this study, little was known about toenail and fingernail growth rates so the purpose of the study was to estimate the average growth rate of fingernails and toenails and to examine factors that may influence nail growth rate. Study participants were twenty-two healthy American young adults. The participants marked their nails close to the proximal nail fold with a provided nail file using a standardized protocol. Participants recorded the date and distance from the proximal nail fold to the mark at one to three months with the average time frame between baseline and final measurement as 64 days (range: 33 to 89 days). Nail growth was calculated based on the study participants recorded distance and time between the measurements of date and the distance from the proximal nail fold to the mark. The results were reported in millimeters per month, a month was defined as 30 days. Information was obtained on the nail growth rate of 195 fingernails and 188 toenails from twenty-two participants. With this study, it was observed that the “average fingernail growth rate 3.47 mm/month) was over twice as fast as that of toenails (1.62 mm/month), P < 0.01.” Also, it was determined that, “Younger age, male gender, and onychophagia were associated with faster nail growth rate; however, the differences were not statistically significant.”¹² There were some limitations noted. Study participants were young adults and therefore results were not generalizable to children or the elderly. Another limitation was that, as shown in previous studies, nail growth rate may be modified by other factors such as race, pregnancy, and disease status. Additionally, the small sample size limited the ability to measure the differences in factors noted above and nail growth rate based on self-measurements may have inherent errors. Lastly, follow-up time was short and limited the ability to determine the possible variation in nail growth rate across seasons and climates as compared in previous studies.

Eekhof et al updated the Cochrane review 'Surgical treatments for ingrowing toenails.' Two authors independently selected studies that included randomized control trials (RCT) of non-surgical and surgical interventions for ingrowing toenails. Search of the databases to January 2010 included Cochrane Skin Group Specialized Register, CENTRAL in The Cochrane Library, MEDLINE, and EMBASE. In addition, searches of CINAHL, WEB of SCIENCE, ongoing trials databases, and the reference articles were updated. Methodological quality, and data were extracted from the selected studies. This update included 24 RCT studies, with a total of 2,826 participants, 7 of the studies were included in the previous review. Five studies were on non-surgical interventions, and 19 were on surgical interventions.

The comparison of non-surgical interventions with surgical interventions revealed that surgical interventions are more effective in preventing the recurrence of an ingrowing toenail and surgical interventions are most likely to be of use when the ingrowing toenail is at a more severe stage of development (stage II and stage Ill). In the studies comparing a surgical intervention to a surgical intervention with the application of phenol, (phenolization), authors determined that the addition of phenol is probably more effective in preventing recurrence and regrowth of the ingrowing toenail.¹¹ One limitation noted is there is only one study in which the surgical interventions in both study arms were equal, thereby more studies must be done to confirm these outcomes. Also, although there are different non-surgical and surgical interventions for ingrowing toenails that are available, there is no agreement about a standard first choice treatment.

The recurrence rate, for ingrown toenail, with a simple partial nail avulsion is approximately 70 percent.⁸ A study by Khan et al revealed that at follow-up at one and six months 5% of the patients had spike formation and all of them belonged to the partial nail avulsion alone group. Between the groups studied, patients with surgery with phenolization and patients without phenolization, the p-value for recurrent disease was 0.027 considered significant and showed that partial avulsion with phenol application had better outcome compared to partial nail avulsion without the application of phenol.¹³ Other studies have shown that the surgical technique of partial lateral nail avulsion and matrixectomy has been shown to achieve success in the treatment of ingrown nails.¹⁴Avulsion of the nail plate may be initially performed to allow full exposure of the nail matrix to visualize the nail bed and nail matrix in order to look for pathologies originating in either the nail bed or the nail matrix, which may include inflammatory dermatoses, (e.g., chronic plaque psoriasis), infections, connective tissue diseases (e.g., systemic sclerosis, lupus erythematosus (SLE), dermatomyositis (DM), primary Sjogren’s syndrome), and tumors.¹ Avulsion of the nail plate may also be performed in order to obtain a biopsy on the nail bed or matrix for diseases with nail deformities associated with dermatologic conditions, like psoriasis and lichen planus nail dystrophy, as well as, nail unit tumors, nevi, suspected malignant melanoma, longitudinal melanonychia and pachyonychia congenita.^2,7,9,10 Total nail avulsion is a method to examine and treat various nail unit pathologies; (Chronic onychomycosis and periungual warts) however, the literature notes that partial avulsion procedure, due to its simplicity and fewer postoperative complications, is often found to be preferred. Also noted, careful patient selection and maintenance of asepsis during and after the procedure and gentle handling of the matrix and nail folds are noted to promote positive outcomes of the procedure. Nail generation depends on a patient’s age, gender, and habits. Complete regrowth of an avulsed fingernail usually requires 4 to 5 months, whereas the toenail may require up to 10 to 12 months.^7,10A partial nail avulsion, used to treat a symptomatic infected ingrown toenail is a temporary relief for ingrown toenails as the nail matrix often grows back to its original thickness and the offending margin may again become a problem, resulting in another ingrown nail. When a nail avulsion is done, the matrix is not typically destroyed, thus leading to regrowth of the spicule or nail plate.^13,14 For those patients who have failed conservative therapy or have a symptomatic presentation of an ingrown toenail that is moderate to severe³; a surgical intervention such as removal of granulation tissue of the affected nail fold and a partial nail avulsion of the affected nail edge and with the application of a chemical, surgical, or electrocautery matrixectomy to prevent recurrences, may be required.¹³ A Cochrane systematic review found that a partial nail avulsion combined with phenolization is more effective at preventing symptomatic recurrence of an ingrown nail than surgical excision/removal without phenolization (one in 25 patients with recurrence versus eight in 21 without phenolization).¹¹ In a 2019 publication, the American Academy of Family Physicians reported that matrixectomy prevents recurrence of an ingrown nail and can be performed through surgical, chemical, or electrosurgical means.

The American Academy of Dermatology (AAD) Association Administrative Regulations for Evidence-based Clinical Practice Guidelines addresses the safety of the clinical use of some of the more commonly used local anesthetics (i.e., topical, infiltrative, nerve blocks, and infiltrative tumescent) in dermatologic surgeries in the office setting. One hundred sixty-five abstracts were retained and used. A secondary manual search identified 36 additional relevant studies. Once the full data set of 201 studies was made in proper order and categorized, each study was reviewed and ranked based on relevance, then the level of evidence for the clinical questions were determined by the workgroup.

Clinical recommendations per the workgroup were developed based on the best available evidence. The strength of recommendation was ranked as A, B, or C. Where documented evidence-based data were not available, or showed inconsistent or limited conclusion, expert opinion and medical consensus were also considered.¹⁵This study supports the recommendations for the use of topical anesthesia in dermatologic surgery. Infiltrative anesthesia is considered safe and recommended for office-based dermatologic procedures, including but not limited to obtaining a biopsy specimen, excision, wound closure, tissue rearrangement, skin grafting, cauterization, nonablative laser, and ablative skin resurfacing is a strength of recommendation of “C” and a level of evidence of “III” referenced by expert opinion.¹⁵Nail trephination or releasing the hematoma is a technique to relieve painful pressure by draining the blood beneath the nail. Onumah et al describes the management of subungual hematomas which depends on their size, location, and presentation. A hematoma that occupies 25% or more of the nail bed is evacuated by creating one or two small puncture holes through the nail plate, to allow drainage of the hematoma.⁷ Tos et al describe strategies in treating nail bed and fingertip injuries. If the hematoma is 50% or more of the underlying nail area, depending on the type and degree of injury, the nail plate may need to be surgically removed. When there is greater than 50% involvement of the nail plate and associated fracture of the distal phalanx, the authors suggest the examination of the complete nail bed. Although studies show that it may be necessary to have the nail removed to examine the nail bed for injury, and subsequent repair, the authors noted that this is no longer a routine practice if the nail edges or margins are intact.

Analysis of Evidence (Rationale for Determination)

Partial or complete avulsion of the nail plate with the use of a local anesthetic may be performed to allow the exposure of the nail matrix for examination of the nail bed enabling visualization of the nail bed and nail matrix in order to look for pathologies originating in either the nail bed or the nail matrix. Studies have shown that partial or complete nail avulsion is considered medically reasonable and necessary for the examination of the nail bed and for the treatment of traumatic nail injury, subungual abscess and/or hematoma, subungual tumors, onychogryphosis, onychauxis, onycholysis, symptomatic congenital nail dystrophies or nail deformities associated with dermatologic conditions. Studies have shown that complete regrowth of an avulsed fingernail usually requires 4 to 5 months, and the toenail may require up to 8 to 12 months. Based on these studies, a repeat nail avulsion on the same toe or finger following a complete nail avulsion performed more frequently than every 8 months (32 weeks) for toenails or 4 months (16 weeks) for fingernails is considered not medically reasonable and necessary.

For those patients who have failed conservative therapy or have a symptomatic presentation of an ingrown toenail that is too severe for a non-surgical intervention, a surgical intervention, such as removal of granulation tissue of the affected nail fold and a partial nail avulsion of the affected nail edge either with or without the application of a chemical, surgical, or electrocautery matrixectomy may be considered medically reasonable and necessary for the treatment of a symptomatic ingrown toenail or fingernail.

Proposed Process Information

Synopsis of Changes

Changes	Fields Changed
	N/A

Associated Information

Sources of Information

Bibliography

Open Meetings

Contractor Advisory Committee (CAC) Meetings

MAC Meeting Information URLs

Proposed LCD Posting Date

Comment Period Start Date

Comment Period End Date

Reason for Proposed LCD

Requestor Name	Requestor Letter
	View Letter

Requestor Information

Contact for Comments on Proposed LCD

Coding Information

ICD-10-CM Codes that Support Medical Necessity

ICD-10-CM Codes that DO NOT Support Medical Necessity

Additional ICD-10 Information

General Information

Associated Information

Please refer to the related Local Coverage Article: Billing and Coding: Surgical Treatment of Nails A57666 for documentation requirements, utilization parameters and all coding information as applicable.

Sources of Information

Novitas Solutions JH LCD L32637, Nail Avulsion

Other Contractor’s Policies

Contractor Medical Directors

Bibliography

Onumah N. Nail Surgery. emedicine.medscape.com Updated Feb 15, 2019. Accessed May 15, 2020. https://emedicine.medscape.com/article/1126725-treatment#d10.
Grover C, Chaturvedi UK, Reddy BS. Nail Biopsy: A user’s manual. Indian J Dermatol Venereol Leprol. 2018;9:3-15.
Geizhals S, Lipner S. Review of onychocryptosis: epidemiology, pathogenesis, risk factors, diagnosis and treatment. eScholarship.org. Dermatology online Journal Published September 2019;25(9):1. https://escholarship.org/uc/item/9985w2n0.
Baswan S, Kasting GB, Li SK, et.al. Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases. Mycoses. 2017;60(5):284-295. doi:10.1111/myc.12592.
Foot complications ADA https://www.diabetes.org/. Accessed May 6, 2020.
Mayeaux EJ Jr, Carter C, Murphey TE. Ingrown toenail management. Am Fam Physician. 2019 Aug 1;100(3): online. https://www.aafp.org/afp/2019/0801/p158-s1.html.
Tos P, Titolo P, Chirila NL, et al. Surgical treatment of acute fingernail injuries. J Orthopaed Traumatol. 2012;13(2):57-62. https://doi.org/10.1007/s10195-011-0161-z.
Vlahovic TC, Current concepts in nail surgery. Podiatry Today. 2016;29(7):72-75. https://www.podiatrytoday.com/current-concepts-nail-surgery. Accessed May 15, 2020.
Dooley TP, Kindt KE, Baratz ME. Subungual tumors. Hand. 2012;7:252-258. Published online:26 May 2012. doi:10.1007/s11552-012-9418-0.
Pandhi D, Verma P. Nail avulsion: Indications and methods (surgical nail avulsion). Indian J Dermatol Venereol Leprol. 2012;78(3):299-308. doi:10.4103/0378-6323.95444.
Eekhof JAH, Van Wijk B, Knuistingh Neven A, van der Wouden JC. Interventions for ingrowing toenails. Cochrane Database of Systematic Reviews 2012;(4). Art. No.: CD001541. doi: 10.1002/14651858.CD001541.pub3.
Yaemsiri S, Hou N, Slining MM, He K. Growth rate of human fingernails and toenails in healthy American young adults. JEADV. 2010;24(4):420-423.
Khan IA, Shah SF, Waqar SH, et al. Treatment of ingrown toe nail-comparison of phenolization after partial nail avulsion and partial nail avulsion alone. J Ayub Med Coll Abbottabad. 2014;26(4):522-525. http://www.ayubmed.edu.pk/JAMC/26-4/Irshad.pdf.
Zuber T. Ingrown toenail removal. American Family Physician, June 15, 2002;65(12):2547-2550.
Kouba DJ, LoPiccolo MC, Alam M, et al. Guidelines for the use of local anesthesia in office-based dermatologic surgery. J Am Acad Dermatol. 2016;74:1201-1219.
Abdullah l, Abbas O. Common nail changes and disorders in older people. Can Fam Physician. 2011;57:173-181.
Dabrowskia M, Litowinska A. Recurrence and satisfaction with sutured surgical treatment of an ingrown toenail. Annals of Medicine and Surgery. 2020;56:152-160. https://doi.org/10.1016/j.amsu.2020.06.029.
Karaca N, Dereli T. Treatment of ingrown toenail with proximolateral matrix partial excision and matrix phenolization. Ann Fam Med. 2012;10(6):556-559. doi:10.1370/afm.1406.
Kline A, Onychocryptosis: A simple classification system. The Foot and Ankle Journal. 2008;1(5):6.
Lee DJR, Arbache ST, Quaresma MV, Nico MMS, Gabbi TVB. Nail apparatus melanoma: Experience of 10 years in a single institution. Skin Appendage Disord. 2019;5:20-26. doi: 10.1159/000488722.
Mefford AM, Kasdan ML, Wilhelmi B. Photo-documentation of thumbnail regrowth after surgical avulsion: Case report and literature review. eplasty. Published July 9, 2014. Accessed May 19, 2021.

Revision History Information

Revision History Date	Revision History Number	Revision History Explanation	Reasons for Change
01/30/2022	R4	LCD posted for notice on 12/16/2021 to become effective 01/30/2022. Proposed LCD posted for comment on 07/29/2021.	Creation of Uniform LCDs With Other MAC Jurisdiction
11/28/2019	R3	Revision Number: 3 Publication: November 2019 Connection LCR B2019-031 Explanation of Revision: Based on Change Request (CR) 10901, the LCD was revised to remove all billing and coding and all language not related to reasonable and necessary provisions (“Bill Type Codes,” “Revenue Codes,” “CPT/HCPCS Codes,” “ICD-10 Codes that Support Medical Necessity,” “Documentation Requirements” and “Utilization Guidelines” sections of the LCD) and place them into a newly created billing and coding article. During the process of moving the ICD-10-CM diagnosis codes to the billing and coding article, the ICD-10-CM diagnosis code ranges were broken out and listed individually. In addition, the Social Security Act, Code of Federal Regulations, and IOM reference sections were updated. The effective date of this revision is for claims processed on or after January 8, 2019, for dates of service on or after October 3, 2018. At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination and therefore not all the fields included on the LCD are applicable as noted in this LCD.	Other (Revision based on CR10901)
02/19/2019	R2	Revision Number: 2 Publication: March 2019 Connection LCR B2019-010 Explanation of Revision: Based on a Change Request 10951, the LCD was revised to update the IOM Citation in the “CMS National Coverage Policy” section of the LCD. CMS IOM Publication 100-09, Chapter 5 was removed and CMS IOM Publication 100-04, Chapter 23, Section 20.9 was added. The effective date of this revision is for claims processed on or after 02/19/2019, for dates of service on and after 12/11/2018. 02/19/2019: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination and therefore not all the fields included on the LCD are applicable as noted in this LCD.	Other (Revisions based on Change Request 10951)
01/01/2017	R1	11/16/2016 - For the following CPT/HCPCS codes either the short description and/or the long description was changed: 11750 descriptor was changed in Group 1	Revisions Due To CPT/HCPCS Code Changes

Associated Documents

Attachments
N/A

Related Local Coverage Documents
Articles
A57666 - Billing and Coding: Surgical Treatment of Nails
A58960 - Response to Comments: Surgical Treatment of Nails
LCDs
DL33833 - Surgical Treatment of Nails (MCD Archive Site)

Updated On	Effective Dates	Status
12/10/2021	01/30/2022 - N/A	Currently in Effect	You are here
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

Keywords

N/A

Read the LCD Disclaimer

Please review and accept the agreements in order to view Medicare Coverage documents, which may include licensed information and codes.

LICENSE FOR USE OF PHYSICIANS' CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION ("CPT")

End User Point and Click Amendment:

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

AMA Disclaimer of Warranties and Liabilities.

CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

CMS Disclaimer

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled "I Accept".

LICENSE FOR USE OF CURRENT DENTAL TERMINOLOGY (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org.
Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use. U.S. Government Rights Provisions.
Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.
ADA DISCLAIMER OF WARRANTIES AND LIABILITIES. CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement.

The ADA is a third party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Surgical Treatment of Nails

Document Note

Note History

Contractor Information

LCD Information

Document Information

Issue

CMS National Coverage Policy

Coverage Guidance

Proposed Process Information

Coding Information

Bill Type Codes

Revenue Codes

CPT/HCPCS Codes

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Additional ICD-10 Information

General Information

Revision History Information

Associated Documents

Keywords

Page Help for LCD - Surgical Treatment of Nails (L33833)

Introduction

More information

Tracking Sheet

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS